Letter: lessons from the 'real-world' entecavir therapy in chronic hepatitis B patients--authors' reply
Aliment Pharmacol Ther
.
2016 Apr;43(7):847-8.
doi: 10.1111/apt.13558.
Authors
J Ahn
1
,
M H Nguyen
2
,
J K Lim
3
,
H M Lee
4
,
C Q Pan
5
,
A S Lok
6
Affiliations
1
Division of Gastroenterology & Hepatology, Oregon Health & Science University, Portland, OR, USA. ahnj@ohsu.edu.
2
Division of Gastroenterology & Hepatology, Stanford University, Stanford, CA, USA.
3
Digestive Diseases, Yale University, New Haven, CT, USA.
4
Gastroenterology/Hepatology Division, Tufts Medical Center, Boston, MA, USA.
5
Department of Medicine, NYU Langone, New York, NY, USA.
6
Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA.
PMID:
26932418
DOI:
10.1111/apt.13558
No abstract available
Publication types
Letter
Comment
MeSH terms
Antiviral Agents / therapeutic use*
Female
Guanine / analogs & derivatives*
Hepatitis B, Chronic / drug therapy*
Humans
Male
Substances
Antiviral Agents
Guanine
Grants and funding
P30 DK034989/DK/NIDDK NIH HHS/United States